Aegis patents absorption-enhancing thixotropic aqueous hydrogels

Published: 21-Jan-2013
Ingredients Drug Delivery Pharmaceutical Dosage Forms

Hydrogels serve simultaneously as both delivery vehicle and absorption enhancer


San Diego-based drug formulation technology company Aegis Therapeutics has been awarded US Patent No. 8,329,220 providing proprietary compositions for absorption-enhancing self-assembling aqueous hydrogels useful for extended release, transdermal or transmucosal absorption enhancement for peptide and small molecule drug delivery applications.

The Aegis Hydrogels serve simultaneously as both delivery vehicle and absorption enhancer. In dermal applications, these hydrogels immediately absorb into the skin with no sense of any residue remaining. In sustained release depot applications, unlike current depot matrices that require large gauge needles for delivery, resulting in significant and unnecessary patient discomfort, the thixotropic nature of these gels allows liquid-like flow through fine-gauge needles (28 gauge or 31 gauge) with resumption of the stable gel form immediately upon exiting the needle.

The company is seeking licensees for prescription and OTC applications of the Aegis Hydrogels.

  • Companies:
  • Aegis Therapeutics LLC
See more

You may also like

Drug Delivery

Aegis and Dr Reddys sign drug delivery agreement

Read more
Will give the Indian drugmaker access to US-based Aegis\' Intravail drug delivery technology for certain drugs

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  3. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  4. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
  5. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Drug Delivery

Aegis and Dr Reddys sign drug delivery agreement

Will give the Indian drugmaker access to US-based Aegis\' Intravail drug delivery technology for certain drugs
Manufacturing

ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector

The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Dosage Forms

Dermal drug product for papulopustular rosacea approved in China

The approval brings the product to the Chinese market, where 3.5% of the population suffer from the skin condition
Distribution

Tower Cold Chain launches live tracking and monitoring for pharmaceutical distribution

The upgrade allows customers to access real-time insights into shipments, facilitating the optimisation of cold chain processes
Subscribe now